Clinical trial · Interventional
Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer
Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients
NCT02418247CI-TRIAL-00025565unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The researchers investigated the rate of biochemical remission in patients without radioactive iodine therapy compared to patients with low dose radioactive iodine treatment in differentiated thyroid cancer patients who underwent total thyroidectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Neoplasms | Thyroid Gland Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| I123 | Drug | — | UNRESOLVED |
| I131 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- low dose RAI
- description
- Low dose RAI (radioactive iodine I-131, 30mCi) will be given to ablate remnant thyroid tissue.
- interventionNames
- Drug: I131
- type
- SHAM_COMPARATOR
- label
- diagnostic RAI
- description
- Diagnostic RAI (radioactive iodine I-123, 2-6mCi) will be given to achieve postRAI scan.
- interventionNames
- Drug: I123
Primary outcomes (1)
- measure
- Biochemical Remission Rate
- timeFrame
- within 1 year since first thyroid hormone withdrawal regardless of radioactive iodine administration
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 79 Years
Show eligibility criteria text
Inclusion Criteria: * patients with differentiated thyroid cancer * recently underwent total thyroidectomy (within 6 months) * pathological criteria 1. T1bN0 : Tumor size 1-2cm with no microscopic extension with multifocality (within three foci) 2. T3N0 : Tumor size \<=2cm with microscopic extension (less than strap muscle) 3. T1-3N1a : 3 or less micrometastatic lymph node Exclusion Criteria: * differentiated thyroid cancer with aggressive variant, poorly differentiated thyroid cancer, medullary thyroid cancer, anaplastic thyroid cancer * gross extension (strap muscle or more) * thyroid cancer with distant metastasis * previous remote history of thyroid cancer surgery * history of cervical external beam radiation therapy * previous history of comorbid cancer within 5 years * renal insufficiency (Ccr \<30ml/min) * women with pregnancy or breast feeding
References
Publications (0)
Data not yet available
No reference posted for this study.